Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.Published in:Obesity (19307381), 2023, v. 31, n. 1, p. 111, doi. 10.1002/oby.23621By:Lingvay, Ildiko;Brown‐Frandsen, Kirstine;Colhoun, Helen M.;Deanfield, John;Emerson, Scott S.;Esbjerg, Sille;Hardt‐Lindberg, Søren;Hovingh, G. Kees;Kahn, Steven E.;Kushner, Robert F.;Lincoff, A. Michael;Marso, Steven P.;Fries, Tea Monk;Plutzky, Jorge;Ryan, Donna H.Publication type:Article